142 related articles for article (PubMed ID: 37329351)
1. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan Pancreas Society.
Tomimaru Y; Eguchi H; Shimomura Y; Kitamura T; Inoue Y; Nagakawa Y; Ohba A; Onoe S; Unno M; Hashimoto D; Kawakatsu S; Hayashi T; Higuchi R; Kitagawa H; Uemura K; Kimura Y; Satoi S; Takeyama Y;
J Gastroenterol; 2023 Aug; 58(8):790-799. PubMed ID: 37329351
[TBL] [Abstract][Full Text] [Related]
2. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real-world data.
Tomimaru Y; Eguchi H; Inoue Y; Nagakawa Y; Ohba A; Takami H; Unno M; Yamamoto T; Kawakatsu S; Hayashi T; Higuchi R; Kitagawa H; Hattori S; Fujii T; Hirooka Y; Igarashi H; Kitano M; Kuroki T; Masamune A; Shimizu Y; Tani M; Tanno S; Tsuji Y; Yamaue H; Satoi S; Takeyama Y;
Cancer; 2023 Mar; 129(5):728-739. PubMed ID: 36504020
[TBL] [Abstract][Full Text] [Related]
3. Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: Analysis using inverse probability of treatment weighting.
Kondo N; Uemura K; Sumiyoshi T; Okada K; Seo S; Otsuka H; Kawano R; Murakami Y; Takahashi S
J Hepatobiliary Pancreat Sci; 2022 Aug; 29(8):911-921. PubMed ID: 35435318
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma.
Matsushima H; Adachi T; Hidaka M; Yamashita M; Hamada T; Fukui S; Tanaka T; Imamura H; Yoshino K; Kugiyama T; Kitasato A; Hara T; Soyama A; Kobayashi K; Sumida Y; Kuroki T; Eguchi S
Anticancer Res; 2022 Jun; 42(6):3133-3141. PubMed ID: 35641261
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
[TBL] [Abstract][Full Text] [Related]
6. Identification of an Immune-Related BAT Signature for Predicting Adjuvant Chemotherapy Response and Overall Survival in Patients with Resected Ductal Adenocarcinoma of the Pancreas.
Pu N; Chen Q; Yin H; Zhang J; Zhao G; Habib JR; Chen J; Yu J; Lou W; Wu W
J Gastrointest Surg; 2022 Apr; 26(4):869-886. PubMed ID: 35059985
[TBL] [Abstract][Full Text] [Related]
7. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
8. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
Liang L; Ding Y; Yu Y; Liu K; Rao S; Ge Y; Zeng M
BMC Med Imaging; 2021 Apr; 21(1):75. PubMed ID: 33902469
[TBL] [Abstract][Full Text] [Related]
9. Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer.
Ma SJ; Oladeru OT; Miccio JA; Iovoli AJ; Hermann GM; Singh AK
JAMA Netw Open; 2019 Aug; 2(8):e199126. PubMed ID: 31411712
[TBL] [Abstract][Full Text] [Related]
10. Completion of adjuvant therapy in patients with resected pancreatic cancer.
DePeralta DK; Ogami T; Zhou JM; Schell MJ; Powers BD; Hodul PJ; Malafa MP; Fleming JB
HPB (Oxford); 2020 Feb; 22(2):241-248. PubMed ID: 31563326
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study.
Pu N; Wu W; Liu S; Xie Y; Yin H; Chen Q; He T; Xu Z; Wang W; Yu J; Liu L; Lou W
Int J Surg; 2023 Oct; 109(10):3137-3146. PubMed ID: 37418574
[TBL] [Abstract][Full Text] [Related]
12. Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience.
Xia BT; Ahmad SA; Al Humaidi AH; Hanseman DJ; Ethun CG; Maithel SK; Kooby DA; Salem A; Cho CS; Weber SM; Stocker SJ; Talamonti MS; Bentrem DJ; Abbott DE
Ann Surg Oncol; 2017 Sep; 24(9):2770-2776. PubMed ID: 28600732
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of completion pancreatectomy for recurrence of adenocarcinoma in the remnant pancreas.
Nakayama Y; Sugimoto M; Gotohda N; Konishi M; Takahashi S
J Surg Res; 2018 Jan; 221():15-23. PubMed ID: 29229121
[TBL] [Abstract][Full Text] [Related]
14. Early versus delayed initiation of adjuvant treatment for pancreatic cancer.
Kim HW; Lee JC; Lee J; Kim JW; Kim J; Hwang JH
PLoS One; 2017; 12(3):e0173960. PubMed ID: 28301556
[TBL] [Abstract][Full Text] [Related]
15. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
16. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
17. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
[TBL] [Abstract][Full Text] [Related]
18. Surrogacy of Recurrence-free Survival for Overall Survival as an Endpoint of Clinical Trials of Perioperative Adjuvant Therapy in Hepatobiliary-pancreatic Cancers: A Retrospective Study and Meta-analysis.
Imamura T; Ohgi K; Mori K; Ashida R; Yamada M; Otsuka S; Uesaka K; Sugiura T
Ann Surg; 2024 Jun; 279(6):1025-1035. PubMed ID: 37638472
[TBL] [Abstract][Full Text] [Related]
19. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX.
Lee SH; Hwang DW; Yoo C; Kim KP; Kang S; Jeong JH; Oh D; Song TJ; Lee SS; Park DH; Seo DW; Park JH; Song KB; Lee JH; Lee W; Park Y; Kwak BJ; Chang HM; Ryoo BY; Kim SC
Cancer Res Treat; 2023 Jul; 55(3):956-968. PubMed ID: 36915253
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
Hammad AY; Hodges JC; AlMasri S; Paniccia A; Lee KK; Bahary N; Singhi AD; Ellsworth SG; Aldakkak M; Evans DB; Tsai S; Zureikat A
JAMA Surg; 2023 Jan; 158(1):55-62. PubMed ID: 36416848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]